RxSight Inc (NAS:RXST)

$ 56.45 2.12 (3.9%) Market Cap: 2.24 Bil Enterprise Value: 2.02 Bil PE Ratio: 0 PB Ratio: 8.13 GF Score: 58/100

Q2 2024 Rxsight Inc Earnings Call Transcript
Aug 05, 2024

$40.78 (-2.37%)

Earnings
Q1 2024 Rxsight Inc Earnings Call Transcript
May 06, 2024

$62.84 (+1.88%)

Earnings
Q4 2023 Rxsight Inc Earnings Call Transcript
Feb 28, 2024

$56.39 (-2.64%)

Earnings
Rxsight Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Q3 2023 Rxsight Inc Earnings Call Transcript
Nov 09, 2023

$23.8 (-4.19%)

Earnings
Q2 2023 Rxsight Inc Earnings Call Transcript
Aug 07, 2023

$28.84 (-4.09%)

Earnings
Rxsight Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Q1 2023 Rxsight Inc Earnings Call Transcript
May 09, 2023

$19.25 (-0.82%)

Earnings
Rxsight Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 19, 2023
Rxsight Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Q4 2022 Rxsight Inc Earnings Call Transcript
Mar 06, 2023

$15.69 (+12.96%)

Earnings
Rxsight Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Q3 2022 Rxsight Inc Earnings Call Transcript
Nov 07, 2022

$12.62 (+7.86%)

Earnings
Q2 2022 Rxsight Inc Earnings Call Transcript
Aug 08, 2022

$15.65 (-0.32%)

Earnings
Q1 2022 Rxsight Inc Earnings Call Transcript
May 05, 2022

$10.61 (-10.54%)

Earnings

Rxsight Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 07:15PM GMT

Release Date Price: $13.81 (+3.29%)

Transcript 8-K

Robert Justin Marcus

JPMorgan Chase & Co, Research Division - Analyst

Hello, everyone. I'm Robbie Marcus, the med tech analyst at JPMorgan. Happy to introduce our next presentation, company is RxSight, I'm going to bring up CEO, Ron Kurtz, and then we'll do some Q&A. Ron?

Ronald M. Kurtz

RxSight, Inc. - President, CEO & Director

Thank you very much, Robbie, and thank you for having us at the conference. These are forward-looking statements.

RxSight is focused on growing the premium cataract surgery market, which is the most profitable segment of the highest volume surgical procedure in ophthalmology. Our strategy is based on delivering both better medicine for patients and better business results for doctors and practices, an approach that our team has used previously to build high-margin premium pay businesses in ophthalmology over the past 20 years. As we will discuss, RxSight's first-in-class light adjustable lens or LAL, delivers unparalleled visual results for patients and drives growth of premium pay procedures that are critical to

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.